Measuring-equipment maker Renishaw has seen profits leap, but investors are sceptical about the prospects for drugmaker GSK.
Recent articles GlaxoSmithKline PLC
Glaxo’s chief executive has stepped down after nine years at the top. Has he left the pharma giant in good health? Alex Rankine reports.
When it comes to ridiculous executive pay, GlaxoSmithKline still doesn’t get it, says Merryn Somerset Webb. But they’re not the only ones.
Ed Bowsher explains the ‘secret weapon’ that could help private investors generate excellent market-beating returns.
The boss of pharmaceutical giant GSK has hinted the company could be split in two. That would be great news for shareholders, says Ed Bowsher.
Bank shares might look cheap right now, but don’t be tempted. There are better places to put your money, says Ed Bowsher. Here, he picks two stocks to consider instead.
There are lots of things to like about GlaxoSmithKline, but the giant pharma is also facing some big challenges, says Phil Oakley. So, should you buy the shares?
Ed Bowsher explains what’s going on in the pharmaceuticals industry, and picks his favourite stock in the sector.
Ed Bowsher explains the idea behind Warren Buffett’s ’20-stock punchcard’ investment theory, and highlights two companies that fit the bill nicely.
With pharmaceutical stocks still looking cheap and some very smart deals being done, it’s a good time to buy in to the sector. John Stepek explains how.
You can still find value in some UK stocks, says Ed Bowsher. Here, he explains where you should be looking, and picks three of the best stocks to buy now.
GlaxoSmithKline has had a rotten time recently. But it’s still got plenty going for it. And now could prove a very good time to buy, says Ed Bowsher.
China has taken Western pharmaceutical companies to task over alleged corruption in the country.
The Chinese government has accused pharma giant GlaxoSmithKline of paying $489m in bribes to doctors and lawyers in order to boost sales and profits.